Seaport Therapeutics Posts Positive Phase 1 Data Seaport Therapeutics (Apr 2, 2026) reported no dose-limiting toxicities in 18 patients in Phase 1 of GlyphAgo; next catalysts: full dataset and Phase 2 plan.

Seaport Therapeutics Posts Positive Phase 1 Data: Seaport Therapeutics (Apr 2, 2026) reported no dose-limiting toxicities in 18 patients in Phase 1 of GlyphAgo; next catalysts: full dataset and Phase 2 plan. 👈 Read full analysis #SeaportTherapeutics #Phase1 #ClinicalTrials #GlyphAgo #Biotech

Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression - PharmaTimes First patient dosed in BUOY-1 study targeting MDD with or without anxious distress

#mentalhealth #SeaportTherapeutics #phase2btrial #GlyphAllo #BUOY1study #MDD #anxiousdistress #allopregnanolone #majordepressivedisorder #allopregnanolone #rapidantidepressant #anxiolytic #HAMD17 #depressionratingscale #CNSclinicaltrials #depression #anxiety
pharmatimes.com/news/seaport...